Device type · GGN
Plasma, Coagulation Control
Last checked: Nov 20, 2026Source: openFDAMethods & limitations
Product code
GGN
Hematology
Device class
Class II
FDA decisions since 2015
6
510(k), De Novo and PMA
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- Plasma, Coagulation Control
- Product code
- GGN
- Device class
- Class II
- Review panel
- Hematology
- Regulation
- 21 CFR 864.5425
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for GGN
Latest FDA decisions
K170864 · Decided Jun 21, 2017 · 90 days after receipt
Device type: Plasma, Coagulation Control (GGN) · Laboratory Medicine & Pathology
K163498 · Decided Mar 16, 2017 · 93 days after receipt
Device type: Plasma, Coagulation Control (GGN) · Laboratory Medicine & Pathology
K161316 · Decided Feb 23, 2017 · 288 days after receipt
Device type: Plasma, Coagulation Control (GGN) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
No reports to chart for this view.
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
No manufacturers to rank.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
No patient problems coded.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- 5-PLASMA Bivalirudin Control, Model Number 5D-44905Open, Classified
Z-2896-2026 · Started Jul 1, 2026 · Posted by FDA Aug 5, 2026
Reason given: Stability issues with the reconstituted lyophilized human plasma and bivalirudin matrix have been identified. These stability issues lead to a degradation of measurable bivalirudin in the controls, calibrators, and linearity values.
Cause as FDA categorized it: Process control
- directCHECK ACT-LR whole blood quality control, level 2 Model/Catalog Number: DCGLR-2Open, Classified
Z-2460-2026 · Started Apr 30, 2026 · Posted by FDA Jun 16, 2026
Reason given: Assayed Whole blood control contains labeling with incorrect performance range.
Cause as FDA categorized it: Process control
- BIOPHEN UFH Control PlasmaTerminated
Z-1743-2022 · Started Jun 28, 2022
Reason given: Incorrect product labeling was included in the package.
Cause as FDA categorized it: Under Investigation by firm
13 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.